This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Celsion's Shameless Spin Job (Update)

Stocks in this article: CLSN

Updated with new information.

LAWRENCEVILLE, NJ ( TheStreet) -- Celsion (CLSN) is so disappointing.

Here I thought Celsion was doing the honorable thing by making no excuses for the failure of its Thermodox liver cancer therapy. Last January, CEO Michael Tardugno told investors, straight up, that data from the Thermodox phase III study weren't close to being strong enough to support approval filings in the U.S. or Europe. He didn't offer any spin, he didn't try to data-mine results seeking a desperate glimmer of hope. Thermodox failed and that was that.

All that goodwill was thrown away Tuesday. Celsion now says a "post analysis" of the failed phase III study shows Thermodox did shrink liver tumors in a subgroup of patients who underwent radio-frequency ablation (RFA) for at least 45 minutes. Pity the poor patients who only had their liver tumors cooked for 44 minutes, apparently.

This is not just ordinary data-mining. This is data-mining so deep and ridiculous that Celsion may need to list itself on the Shanghai stock exchange.

"We have completed a thorough review of the HEAT Study and there is clear evidence that ThermoDox can benefit patients when RFA is optimized," said Celsion's chief medical officer Nicholas Borys, in a statement. Too bad the press release didn't come with a laugh track attached.

The graph below, which comes directly from a previous Celsion presentation of Thermodox clinical data, explains why the "45 minute RFA" subgroup analysis is a complete farce. Credit for finding this slide goes to biotech investor David Sobek of Sobek Analytics. You can and should follow Sobek on Twiter at @dsobek.

What you're looking at is the pharmacokinetics of Thermodox. In other words, how much Thermodox (i.e. doxorubicin) gets into a patient's bloodstream following RFA treatment. What you see, clearly, from the graph is patients get the vast majority of Thermodox in the first 45 minutes of RFA treatment. If this is true, then extending RFA treatment beyond 45 minutes is futile and Celsion's spin-job is ludicrous.

Of course, we all know what's going on here. Celsion executives are staring at the end of their careers, so they're desperate to prevent the compensation spigot from being turned off. Celsion has $46 million dollars left to spend, so better that money be funneled into the bank accounts of Tardugno and his crew instead of being returned to shareholders or creditors.

Celsion fired one-third of its workforce today, thereby reducing overhead even further and preserving more money for executive salaries.

Even better if Celsion can actually fool new investors into providing more funding. If that happens, the Thermodox charade might be extended indefinitely. Hell, Tardugno might even convince his sycophantic board of directors to pay him a cushy bonus.

I hoped Celsion would be different. Instead, the actions of its executives are just shameless.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs